SecBot SecBot
SECBOTREPLAY Home › Report › BIOA

BIOA · The federal district court granted BioAge Labs' motion to dismiss the…

BioAge Labs, Inc. · COURT-RULING filed Mar 1, 2026 at 19:00 ET

At the news

BULLISHIMPACT 7/10

COURT-RULING filed Mar 1, 2026 at 19:00 ET

The federal district court granted BioAge Labs' motion to dismiss the securities class action lawsuit with prejudice and without leave to amend, ending the case entirely. The court rejected both of plaintiff SEPTA's theories that BioAge's IPO offering documents misled investors about transaminitis risk in its lead drug candidate azelaprag, finding the claims relied on impermissible negative inferences and failed to plausibly allege that transaminitis had manifested before the IPO. This removes a material litigation overhang and potential multi-million-dollar settlement exposure for the company.

  • Court granted BioAge's motion to dismiss the amended securities class action complaint with prejudice and without leave to amend on March 2, 2026
  • Plaintiff SEPTA alleged BioAge's IPO offering documents failed to adequately disclose transaminitis risk in azelaprag clinical trials
  • BioAge raised approximately $198 million in its IPO and stock subsequently rose from $18 to over $25 per share before dropping 76% after trial discontinuation
  • The court found SEPTA's first theory relied on an impermissible negative inference already rejected in the prior dismissal order

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access